Introduction {#s1}
============

New drugs can be designed via traditional receptor structure-based virtual screening, which enables the discovery of bioactive compounds that bind the target protein, but they can also originate from reverse virtual screening, which finds the unknown protein targets of active compounds or additional targets of existing drugs (drug repositioning; Hurle et al., [@B71]). Among the 84 drug products introduced to the market in 2013, new indications of existing drugs accounted for 20%, implying that drug repositioning plays a key role in drug discovery (Graul et al., [@B60]; Li J. et al., [@B100]). The majority of drugs or bioactive compounds exert their functions by interacting with protein targets. With an increasing number of drugs showing the ability to target multiple proteins, target identification plays an important role in the fields of drug discovery and biomedical research (Wang J. et al., [@B172]). Many reverse screening methods can be used to search for the protein targets of molecules (Ziegler et al., [@B211]), although the earliest approaches involved expensive and time-consuming biological assays (Drews, [@B35]). However, with the continuous development of Big Data and computational techniques, computer-aided reverse screening methods are playing an increasingly important role in the prediction of the off-target effects and side effects of drugs as well as in drug repositioning (Rognan, [@B146]; Liu et al., [@B111]; Schomburg and Rarey, [@B155]).

These computational methods can be divided into three classes according to their underlying principles: shape screening, pharmacophore screening, and reverse docking. In the absence of receptor crystal structures, shape or pharmacophore screening facilitates the discovery of the potential targets of a query molecule by comparing its overall shape or key pharmacophore features with those of the compounds from a ligand database annotated with target information (Schuffenhauer et al., [@B157]; Hawkins et al., [@B67]; Chen et al., [@B23]). The annotated targets of the matched ligands can then be considered potential targets of the query molecule. Reverse docking, in contrast to the traditional molecular docking used to find the ligands of a target protein, refers to the successive docking of a query molecule into the active pocket of each protein from a protein 3D structure database based on spatial and energy principles to identify protein targets with strong binding affinity as potential targets of the query molecule (Li et al., [@B97]). Reverse screening methods are important computational techniques for identifying new macromolecular targets of existing drugs or active molecules and for analyzing their functional mechanisms or side effects (Patel et al., [@B136]). Based on the principles of the methods and the availability of existing large-scale small-molecule \[e.g., ChEMBL, the European Molecular Biology Laboratory (Gaulton et al., [@B50])\] or macromolecule (e.g., the PDB; Rose et al., [@B147]) databases, researchers worldwide have developed a variety of software and online services for predicting the protein targets of small molecules. Representative examples include SEA (Keiser et al., [@B77]), PharmMapper (Liu et al., [@B108]) and INVDOCK (Chen and Zhi, [@B22]), which are among the earliest tools for shape screening, pharmacophore screening and reverse docking, respectively. In recent years, these three methods have been widely used in the prediction of protein targets to clarify the molecular mechanisms of active small molecules against various diseases (Kharkar et al., [@B79]; Cereto-Massagué et al., [@B13]). Many of these molecules are derived from Chinese herbal medicine, and while their pharmacological or biological activities are known, their cellular and molecular mechanisms remain unclear. For example, Lim et al. ([@B104]) used shape screening to determine that curcumin (compound **1**, Figure [1](#F1){ref-type="fig"}), extracted from Zingiberaceae, suppresses the proliferation of human colon cancer cells by targeting cyclin dependent kinase 2 (CDK2). Marine compounds are another class of bioactive small molecules. For example, wentilactone B (WB, compound **2**) is a tetranorditerpenoid derivative extracted from the marine algae-derived endophytic fungus *Aspergillus wentii* EN-48. Zhang et al. ([@B205]) used reverse docking to discover that this small molecule induces G2/M phase arrest and apoptosis of human hepatocellular carcinoma cells by co-targeting the Ras/Raf/MAPK proteins in their signaling pathways.
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Here, we begin by introducing the basic principles of these three types of reverse screening methods, i.e., shape screening, pharmacophore screening and reverse docking, for the prediction of the protein targets of small molecules. Then, representative and classical software and online services for each method as well as the relevant databases are hierarchically categorized and systematically presented. Finally, we reviewed nearly all articles on the applications of these methods since 2000 and selected some typical examples to illustrate the use of these methods. By statistically analyzing these articles, we reveal the trends in the application of these three methods for computer-aided protein target prediction. In addition, we discuss their shortcomings and possible solutions as well as previous reviews of these reverse screening approaches for predicting the protein targets of small molecules.

Methods {#s2}
=======

Reverse screening to search for unknown targets, unintended targets, or secondary targets of small-molecule drugs can be achieved by shape similarity screening, pharmacophore model screening, or reverse protein-ligand docking (Figure [2](#F2){ref-type="fig"}). These three different calculation approaches are complementary and can be used in conjunction with each other. By comparison, shape, and pharmacophore screening are simpler and faster, while reverse docking is more complex and slower. We will introduce these three methods in detail in the following sections.

![The principle and workflow of shape screening, pharmacophore screening, and reverse docking.](fchem-06-00138-g0002){#F2}

Shape screening
---------------

The basic principle of shape screening, from a two-dimensional (2D) perspective, is that structurally similar molecules may have similar bioactivity by targeting the same proteins. From a three-dimensional (3D) perspective, the basic principle is that molecules with similar volumes may have the potential to bind effectively to spaces of the same or similar size (considering the ligand-induced fit effect; Koshland, [@B85]) in the active pockets of proteins (Shang et al., [@B158]). To use shape screening to predict the targets of small molecules, a small-molecule ligand database annotated with protein targets is necessary. Then, the overall shape similarity of a query molecule to each ligand in the database can be measured individually. Finally, the protein targets for matched molecules with high similarity scores can be considered potential targets of the query molecule (Schuffenhauer et al., [@B157]). Shape screening involves two levels of mapping: the first mapping between the query molecule and the ligands in the database and the second mapping between the matched ligands in the database and their annotated protein targets (Figure [2](#F2){ref-type="fig"}).

Shape similarity comparison is based on the 2D or 3D topological structures of small molecules. Notably, 2D methods were originally created to obtain more of the same part between paired molecules, whereas 3D methods can be used to enhance scaffold diversity (Nettles et al., [@B131]). A universal descriptor for molecular similarity comparison in 2D methods is FingerPrint2D (FP2), which employs a simple bit vector to represent a variety of chemical characteristics and is encoded in a variety of software and databases (Bender et al., [@B6]). The most frequently used type of FP2 is extended-connectivity fingerprints (ECFPs), which are circular fingerprints. ECFPs symbolize circular atomic neighborhoods based on the Morgan algorithm and are designed especially for structural activity modeling (Rogers and Hahn, [@B145]). They have variable length: for example, ECFP4 refers to a diameter of 4 and ECFP6 to a diameter of 6 (Glem et al., [@B57]), both of which are encoded in TargetHunter (Wang L. et al., [@B173]). Molecular ACCess System (MACCS; Durant et al., [@B37]) is another commonly used FP2. It is a structure key-based fingerprint and is encoded in the 2D approach of the ChemMapper server (Gong et al., [@B59]). In addition to FP2, other descriptors are based on 2D topologies or paths, including the daylight fingerprint (<http://www.daylight.com>) encoded in ChemProt 3.0 (Kringelum et al., [@B87]) and the MDL structural key, another 2D descriptor (Durant et al., [@B37]). Structural matching based on 3D topology mainly compares the 3D geometries of the molecules, sometimes with the addition of pharmacophores (Lo et al., [@B114]), ElectroShapes (Armstrong et al., [@B4]), Spectrophores (Smusz et al., [@B163]), or other additional information. For example, WEGA (Yan et al., [@B191]) and gWEGA (Yan et al., [@B190]) compare only the volumes of two molecules, but SHAFTS (Lu et al., [@B118]), encoded in ChemMapper, incorporates pharmacophore matching when calculating the volume similarity.

The similarity of the descriptors in both 2D and 3D methods can be measured by the Tanimoto coefficient. The Tanimoto coefficient represents the ratio of the union to the intersection of the shapes of two molecules (Salim et al., [@B150]). For example, TargetHunter uses the Tanimoto coefficient to calculate the similarity among molecular fingerprints (Wang L. et al., [@B173]). The City-Block distance (CBD, also called the Manhattan or Hamming distance), which represents the difference between the sum of two molecular shapes and twice the overlap of two molecular shapes, can also be used to calculate the molecular similarity (Awale and Reymond, [@B5]). For example, SwissTargetPrediction uses this formula to calculate ElectroShape vectors in 3D comparisons (Gfeller et al., [@B53]).

Shape screening can be divided into two subclasses: indirect target prediction and direct target prediction. Indirect target prediction indicates that the potential targets of the query molecule are manually selected from the annotated protein targets of the matched database ligands. ROCS (Rush et al., [@B149]) and TargetHunter (Wang L. et al., [@B173]) are representative examples. These programs merely calculate the similarity scores between the query molecule and the matched ligands in the database but cannot reveal the complex relationships among the annotated protein targets of multiple matched ligands. In general, the annotated targets of any database ligand are not unique, and a protein target may also be annotated with multiple compounds (Rognan, [@B146]). Therefore, these programs can have high rates of false positives in target prediction and low accuracy in target searching.

Direct target prediction not only calculates the similarity score between the query molecules and the ligands in the database but also estimates the probability that the annotated targets of the matched ligands are targets of the query molecule. This extra process can reduce the false positive rate of target prediction and improve the accuracy of the target search. The probability that the annotated targets of the matched ligands are targets of the query molecule can be evaluated by multiple computational models or algorithms (the dotted line in Figure [2](#F2){ref-type="fig"}). For example, ChemMapper (Gong et al., [@B59]), which is based on a compound-protein network constructed from the top similar structures and their annotated targets, employs a random walk algorithm (Köhler et al., [@B84]) to calculate the probabilities of interaction between the query structure and the annotated targets of the hit compounds. In addition, SwissTargetPrediction (Gfeller et al., [@B53]) and CSNAP3D (Lo et al., [@B114]) use a cross-validation method and a network algorithm, respectively, to assess the probabilities that the annotated targets of the matched ligands are targets of the query molecule.

Because shape screening is based on the comparison of overall molecular shape, it may not be suitable for predicting the potential targets of molecules that are excessively large or small. Judging the potential targets of an oversized molecule is difficult because its best matched ligands usually show a low similarity score, and selecting the potential targets of an undersized molecule is difficult because its matched ligands are numerous with high similarity scores. Shape screening is suitable for predicting potential targets whose available inhibitors have sizes similar to that of the query molecule but is less fit for finding novel targets whose current inhibitors differ greatly in size from the query molecule but whose active pocket space is easily adjusted to bind diverse ligands due to a strong induced-fit effect.

Pharmacophore screening
-----------------------

The basic principle of pharmacophore screening is that the binding of certain drugs with their protein targets is primarily determined by key functional pharmacophores (Rognan, [@B146]). Thus, the matching of these important pharmacophores can be used to search for new targets of small-molecule drugs (Fang and Wang, [@B44]). A pharmacophore is the spatial arrangement of functional characteristics that allows molecules to interact with target proteins in a particular binding mode, such as a hydrophobic center (H), hydrogen bond acceptor vector (HBA), hydrogen bond donor vector (HBD), positively charged center (P), or negatively charged center (N) (Kurogi and Güner, [@B92]). A pharmacophore model is the combination of pharmacophores in a pattern of ligand-protein interaction that give the final pharmacological effect (Leach et al., [@B94]). Similar to a ligand database for shape screening, a pharmacophore database also requires annotation with target protein information. In pharmacophore screening, the pharmacophore features of the query molecule are successively matched with the features of the pharmacophore models in the database. A higher matching degree indicates that the annotated protein target of the matched pharmacophore model has greater potential to be a target of the query molecule (Steindl et al., [@B164]). Pharmacophore screening also undergoes two levels of mapping: the first mapping is between the pharmacophore models of the query molecule and of the ligands in the database, and the second mapping is between the matched pharmacophore models of the ligands in the database and their annotated protein targets (Figure [2](#F2){ref-type="fig"}).

The pharmacophore database is built by pharmacophore modeling. The three construction methods are the use of ligands only, receptor structures only, or co-crystallized complex structures, which can be defined as ligand-based, structure-based and complex-based pharmacophore modeling, respectively. Ligand-based pharmacophore modeling was initially designed and is often used for traditional ligand-based virtual screening; an example is the quantitative structure--activity relationship (QSAR; Pulla et al., [@B140]). The most substantial common features shared by a group of active molecules can be easily extracted by using this method to form a good pharmacophore model to guide the further optimization of active compounds (Leach et al., [@B94]; Gaurav and Gautam, [@B51]). However, this approach is seldom used in reverse pharmacophore modeling due to the arbitrariness of pharmacophore models based on a single protein-annotated ligand.

The other two main methods, the use of only receptor structures and the use of protein-ligand complex structures, are forms of structure-based pharmacophore modeling (Gaurav and Gautam, [@B51]). In receptor-based methods, the pharmacophore features are first extracted from potential binding sites detected by specific protocols, and the pharmacophore models are then derived from the clustering of interaction point information and further refined or validated by using the input of the known ligands and their available or even calculated binding data (Chen and Lai, [@B16]). For instance, Pocket v.2 (Chen and Lai, [@B16]) and Catalyst SBP in Discovery Studio (DS) (BIOVIA, [@B10]) can both produce this type of pharmacophore database. In complex-based methods, pharmacophore models are simply generated via knowledge-based topological rules by using all features, such as hydrogen bonding information, charge, and hydrophobic contacts, based on the interactions between the co-crystallized ligands and receptor atoms (Sutter et al., [@B166]; Meslamani et al., [@B126]). Complex-based pharmacophore modeling is commonly used to construct pharmacophore databases, such as PharmaDB in Discovery Studio (Meslamani et al., [@B126]) and PharmTargetDB in PharmMapper (Liu et al., [@B108]), due to the stronger association between the built pharmacophore models and the experimentally verified ligand-protein interactions, which can improve the accuracy of target prediction.

The matching process between a pharmacophore model of the query molecule and the pharmacophore models in the pharmacophore database considers the alignment of two core components: pharmacophore feature types and the positions of the feature types (Wolber and Langer, [@B186]). The alignment of feature types is the matching between the pharmacophore features shared by the query molecule and the database ligands, such as matching between a hydrophobic feature in the molecular structure and those in database ligand pharmacophore models. The alignment of the feature positions is the pairwise matching of the distances between the fitted feature types in the pharmacophore models (Kabsch, [@B76]). For example, PharmMapper groups pharmacophores into triplets (e.g., H-H-H, H-HBA-HBD) and uses the vertexes of a triangle to represent the pharmacophore feature types and the side length of the triangle to measure the relative positions of these feature types (Liu et al., [@B108]).

In pharmacophore screening, the pairwise fitness score between pharmacophore models can be used directly as a basis for target evaluation. The fitness score includes the scores obtained from both the alignments between feature types and the alignments between the positions of each pair of pharmacophore models from the query molecule and database ligands. Higher fitness scores indicate higher probabilities (Wang X. et al., [@B175]). In addition, other matching information, such as the number of matched features and overall shape similarity, can also be used as additional references for target evaluation (Khedkar et al., [@B80]). If the pharmacophore scoring process does not consider the overall shape of the query molecules, it will be more likely to find pseudo protein targets with high fitness scores for a smaller query molecule because its limited pharmacophore features can be easily matched in the database (Wang X. et al., [@B175]). Thus, the target score must be recalculated to improve the prediction accuracy (the dotted line in Figure [2](#F2){ref-type="fig"}). For example, PharmMapper utilizes a normalized fitness score to re-rank the potential targets by standardizing a normal distribution of the fitness score to achieve a higher accuracy (Wang X. et al., [@B176]).

Since the construction of the pharmacophore database by structure-based pharmacophore modeling is not easy, the development of corresponding tools based on this principle has been somewhat limited. However, compared with shape screening, pharmacophore screening can improve the accuracy of prediction because it focuses on matching the key pharmacophore functional groups. In addition, it can ignore the total size of the molecule. As a result, pharmacophore screening can be used to search for potential targets of a query molecule with a large or small volume and can also be employed to find novel protein targets capable of binding a large diversity of ligands. Although PharmTargetDB, the PharmMapper in-house repository, does incorporate protein structural information, a pharmacophore database can be built to use ligands only. That is, constructing a pharmacophore database based on ligands with currently unavailable target structures is also useful for pharmacophore screening.

Reverse docking
---------------

The basic principle of reverse docking is that the binding strength of a small-molecule ligand and a potential protein target is determined by their interaction energy (docking energy). To use reverse docking to predict the targets of a query molecule, a structure grid database of a large number of protein targets is normally required. Then, the query molecule is individually docked with each protein structure in the database. Each docking score is calculated. Finally, the protein targets are sorted according to their docking energy. Generally, a higher rank indicates a greater probability that the protein is a target of the query molecule. In contrast to shape screening and pharmacophore screening, reverse docking involves one level of mapping, which reflects the direct relationship between the query molecule and the target proteins (Figure [2](#F2){ref-type="fig"}). However, it is a complex process that includes recognition of a binding site, construction of the docking grid, a molecular docking algorithm, docking score calculation and target evaluation, among other steps (Lee et al., [@B95]).

In most cases, the active site of a protein is already known and can be determined from its co-crystallized small-molecule ligand. However, for some *apo*-form structures without co-crystallized ligands, the docking program must first recognize the active binding site of these proteins. If the *apo*-form structure is from a protein for which other co-crystallized structures are available, its active site can also be identified from those protein structures with co-crystallized ligands. Otherwise, *de novo* detection of the active site of the *apo*-form structure is required. The literature describes multiple ways to achieve this task. For example, Wang et al. ([@B169]) uses the "divide-and-conquer" method in idTarget to search the surface structure of the entire protein and possible allosteric structures to find potential binding sites. Kuntz et al. ([@B91]) describes a method that was later used in INVDOCK (Chen and Zhi, [@B22]) to define a binding site by a group of overlapping probe spheres of certain radii, which fill up a cavity and whose inward-facing surfaces cover the van der Waals surfaces of the protein atoms at the interface. Active site recognition is very useful in attempts to dock a query molecule into cavities other than the binding pockets of known ligands, which can increase the diversity of the binding between the query molecule and protein targets and improve the accuracy of reverse docking.

The database of protein targets used in reverse docking can be a library of protein crystal structure grids with recognized binding sites determined by co-crystallized ligands or available cavities. We can build these databases by continuously downloading a series of protein crystal structures from the Protein Data Bank (PDB); the time-consuming human-computer interaction processes (such as the deletion of water molecules, the addition of hydrogen atoms, and energy optimization) can be accomplished by using a molecular docking program, and the protein structure grids are finally generated. Traditional molecular docking programs, such as DOCK (Allen et al., [@B3]), AutoDock (Di Muzio et al., [@B32]), Schrödinger (Schrödinger, [@B156]) and Discovery Studio (BIOVIA, [@B10]), can be used to construct a custom target database for reverse docking to search for potential targets of a small molecule. Alternatively, the protein target database can also be a simply processed, automatically constructed protein structure database, and the grids can be generated after the programmed identification of active sites in the process of reverse docking; an example is the idTarget in-house database (Wang et al., [@B169]). Notably, the lack of a universal protein structure grid database and the need to build a new one for each docking program are the main reasons that reverse docking cannot be used as often as traditional structure-based virtual screening.

At present, reverse screening uses two main types of molecular docking techniques, originally developed in DOCK and AutoDock. DOCK (Ewing et al., [@B41]) adopts a "geometry matching method" to perform molecular docking by complementing the geometric shape of the docking ligands with that of the protein active site, usually including hydrogen binding sites and locally accessible sites (Shoichet et al., [@B161]). The matching process is performed by an "anchor and grow algorithm," in which the anchor is a rigid portion of the ligand that is used to initialize a pruned conformation search, and grow refers to the generation of multiple conformations of the remaining segments to simulate the flexible docking of the ligand (Ewing et al., [@B41]). AutoDock uses a "docking simulation method" that employs the "genetic algorithm" to sample the conformations of a docking molecule inside a grid of the receptor binding pocket (Willett, [@B183]). In this algorithm, the molecule starts randomly at the receptor surface and undergoes orientation, translation and rotation to cause conformational changes until the ideal binding pose with the best binding energy is found (Morris et al., [@B128]). Among three reverse docking programs, INVDOCK (Chen and Zhi, [@B22]) and TarFisDock (Li et al., [@B99]) use the DOCK geometry matching method for molecular docking, while idTarget uses the AutoDock genetic algorithm for reverse docking (Wang et al., [@B169]).

Currently, almost all molecular docking programs can perform flexible-ligand docking due to the small size of the ligands; however, these programs still have difficulty in performing molecular docking with a fully flexible protein. Therefore, depending on the flexibility of the receptor proteins, reverse docking can also be classified into two types: rigid protein docking and semi-flexible protein docking. Although reverse docking with a rigid receptor is fast, it ignores ligand/receptor-induced fit effects. An example of a rigid protein docking program for reverse screening is TarFisDock (Li et al., [@B99]). Reverse docking with semi-flexible receptors can be achieved by various methods such as side-chain rotations (Liu H. et al., [@B106]), stretching of active pocket residues (Halgren et al., [@B64]), and ensemble docking (Lorber and Shoichet, [@B115]). For example, INVDOCK allows the amino acid residues of the receptor binding sites to rotate with the entry of the ligand, thereby simulating the ligand induced-fit conformational changes of receptors (Chen and Zhi, [@B22]). idTarget uses the docking of a query molecule into an ensemble of different receptor crystal structures after clustering (Wang et al., [@B169]) and thus simulates semi-flexible receptor docking by possible binding of the molecule with the distinct locations of the active pocket residues of the receptor in its different structures.

The docking score between a query molecule and receptors is an evaluation criterion for ranking its potential targets in reverse screening. Docking energy is a major method of scoring docking poses and normally refers to the interaction energy between the ligand and protein but may also include the energy of the ligand or the energies of both the ligand and the protein (or a part of the protein such as the binding pocket). For example, INVDOCK evaluates the docking structure by calculating the interaction energy between the ligand and receptor (Chen and Zhi, [@B22]), whereas idTarget scores the docking pose by calculating the energy of the ligand, the protein binding pocket and the interaction between them (Wang et al., [@B169]). According to the principle that the most stable structure has the lowest energy, a more negative docking energy results in stronger binding between the ligand and protein. The docking energy is calculated based on energy functions, which are mainly divided into three types: molecular mechanics energy functions, empirical energy functions, and semi-empirical energy functions. The molecular mechanics energy functions are more comprehensive and are rigorously defined by the sum of terms with clear physical meaning, including bond stretching, angle bending, torsion angles, van der Waals forces, electrostatic interactions, desolvation, or hydrophobic interactions, conformational entropy, and potentially others (Huang and Zou, [@B69]; Wang et al., [@B171]). In reality, the molecular mechanics energy functions used in the docking programs may include only some of these terms. For example, TarFisDock uses energy functions including only van der Waals and electrostatic interaction terms (Li et al., [@B99]). Empirical energy functions comprise weighted energy terms whose coefficients are obtained by reproducing the binding affinities of a benchmark data set of protein-ligand complexes (Gilson et al., [@B54]; Gilson and Zhou, [@B56]). For example, INVDOCK uses an empirical energy function based on simple contact terms, including hydrogen bond and non-bond terms, to calculate the ligand-protein interactive energy as the binding affinity (Chen and Zhi, [@B22]). Semi-empirical energy functions combine some molecular mechanics energy terms with empirical weights and/or empirical functional forms and have been widely used in computational docking methods (Raha and Merz, [@B144]). For example, idTarget follows the AutoDock 4 robust scoring functions (Huey et al., [@B70]) and employs a semi-empirical free energy function that includes hydrogen bonding, electrostatics, desolvation, and torsional entropy, whose weighting coefficients are derived from regression analysis of the experimental binding affinity information (Wang et al., [@B171]). In addition, reverse docking allows visual assessment of the docking poses by analyzing the number of hydrogen bonds, the presence or absence of critical hydrogen bonds and pi-pi conjugation, etc., as in traditional virtual screening, to further assist target evaluation for a more accurate prediction.

Reverse docking considers key elements of both shape screening and pharmacophore modeling. It determines whether or not the size of a query molecule can fit inside the binding pocket of a protein target by docking and scores the interaction of the key pharmacophore groups in the molecule and the targets to perform target evaluation. Thus, reverse docking could be the most comprehensive of the three methods in principle. However, similar to traditional molecular docking, it also has the following shortcomings: incompleteness of the search space, inaccuracy of the scoring function, and extensive calculation (Lee et al., [@B95]). Relative to traditional docking, reverse docking has the additional problem that the sizes of the active pockets of proteins defined by co-crystallized ligands are inconsistent. Even if the docking pockets can be defined as being a universally equal size, the residue density of different protein binding pockets may vary, resulting in differences in the calculation ranges for the binding interaction energies. Therefore, reverse docking suffers from a rationality problem, as it is unable to normalize binding energies for the correct sorting of potential targets. Nevertheless, reverse docking can serve as an effective method to complement shape and pharmacophore screening when the protein structures are available.

Software and online services
----------------------------

Many software programs, some of which are available as online services, can be used for reverse screening to predict protein targets of small molecules, but the numbers of online tools available for the three methods are quite different. Shape screening tools are the most numerous and include more than a dozen, such as ChemProt (Kringelum et al., [@B87]), ROCS (Rush et al., [@B149]), ChemMapper (Gong et al., [@B59]), and the SEA search server (Keiser et al., [@B77]). They are listed in the outer ring of Figure [3](#F3){ref-type="fig"}. By contrast, the only tool available for pharmacophore screening is PharmMapper (Liu et al., [@B108]), as shown in the inner ring of Figure [3](#F3){ref-type="fig"}. The main tools available for target searching by reverse docking are TarFisDock (Li et al., [@B99]), idTarget (Wang et al., [@B169]) and INVDOCK (Chen and Zhi, [@B22]), which are illustrated in the middle ring of Figure [3](#F3){ref-type="fig"}. A few large software packages, such as Schrödinger and Discovery Studio, also contain related modules that perform reverse screening, but they can be used only for the indirect prediction of potential targets of small molecules. These tools require users to build their own databases or perform other relevant processing steps. We have summarized the basic information on these tools, organized according to their characteristics, in Table [1](#T1){ref-type="table"}. In addition, for each type of software and online service, we have provided more detailed descriptions of a few classic representatives.

![Software and online services for shape screening, pharmacophore screening, and reverse docking.](fchem-06-00138-g0003){#F3}

###### 

Characteristics of reverse screening tools.

  **Name**                **Required format**      **Search method**                                                              **Coverage**                                                                                   **Reference website**                                                                                                     **First version**   **Last version**   **State**
  ----------------------- ------------------------ ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------ --------------
  SuperPred               SMILES, Pubchem-Name     2D similarity                                                                  341,000 compounds, 1800 targets, 665,000 compound-target interactions                          <http://prediction.charite.de/>                                                                                           2014                2014               Accessible
  HitPick                 SMILES                   1NN similarity searching and Laplacian-modified naïve Bayesian target models   145,549 chemical-protein interactions collected from STITCH 3.1                                <http://mips.helmholtz-muenchen.de/hitpick/cgi-bin/index.cgi?content=targetPrediction.html>                               2013                2013               Accessible
  ChemMapper              SMILES, MOL2, SDF, SMI   SHAFTS, USR, FP2, MACCS, and random walk algorithm                             Nearly 300,000 chemical structures and \>3 million compounds                                   <http://lilab.ecust.edu.cn/chemmapper/>                                                                                   2013                2016               Accessible
  SEA server              SMILES                   FP2 and BLAST-like model                                                       Hundreds of target-ligand sets                                                                 <http://sea.bkslab.org/>                                                                                                  2007                2007               Accessible
  ReverseScreen3D         SMILES                   Hybrid 2D&3D                                                                   Automatically updated from RCSB PDB                                                            <http://www.modeling.leeds.ac.uk/ReverseScreen3D>                                                                         2011                2011               Inaccessible
  TarPred                 SMILES                   KNN-based data fusion with molecular similarity                                533 individual targets with 179,807 active ligands                                             <http://202.127.19.75:5555/>                                                                                              2015                2015               Inaccessible
  SwissTargetPrediction   SMILES                   Five species, FP2, 3D similarity                                               280,000 compounds and \>2000 targets                                                           <http://www.swisstargetprediction.ch/index.php>                                                                           2014                2014               Accessible
  SwissSimilarity         SMILES                   FP2, five 3D methods                                                           \>30 chemical databases covering drugs, bioactive compounds, etc.                              <http://www.swisssimilarity.ch/>                                                                                          2016                2016               Accessible
  ChemProt                SMILES, name             MACCS, FP2, daylight-like fingerprints                                         \>1.7 million unique chemicals and \>20,000 proteins                                           <http://potentia.cbs.dtu.dk/ChemProt/>                                                                                    2011                2016               Accessible
  TargetHunter            SMILES                   ECFP6, ECFP4, FP2                                                              CHEMBL Version 22                                                                              <http://www.cbligand.org/TargetHunter/>                                                                                   2013                2016               accessible
  CSNAP3D                 SMILES, SDF              3D similarity, network algorithms                                              Based on CHEMBL database                                                                       <http://services.mbi.ucla.edu/CSNAP/index.html>                                                                           2016                2016               accessible
  ROCS                    SDF, MOL2, PDB           3D similarity                                                                  User prepared                                                                                  <https://www.eyesopen.com/rocs>                                                                                           2006                2017               Accessible
  PharmMapper             MOL2, SDF                Pharmacophores                                                                 23,236 proteins covering \>53,000 pharmacophore models                                         <http://lilab.ecust.edu.cn/pharmmapper/>                                                                                  2010                2017               Accessible
  TarFisDock              MOL2                     DOCK4.0                                                                        Based on the PDTD, which contains 1207 entries covering 841 known and potential drug targets   <http://www.dddc.ac.cn/tarfisdock/>                                                                                       2006                2008               Inaccessible
  idTarget                PDB, MOL2, pdbqt, cif    MeDock, divide-and-conquer                                                     All protein structures in the PDB                                                              <http://idtarget.rcas.sinica.edu.tw>                                                                                      2012                2012               Accessible
  INVDOCK                 NA                       DOCK                                                                           An in-house database (9000 protein and nucleic acid entries)                                   <http://bidd.nus.edu.sg/group/softwares/invdock.htm>                                                                      2001                NA                 Accessible
  Discovery Studio        SDF, MOL2, PDB           Pharmacophores                                                                 140,000 receptor-ligand pharmacophore models.                                                  <http://accelrys.com/products/collaborative-science/biovia-discovery-studio/pharmacophore-and-ligand-based-design.html>   2012                2017               Accessible

Shape screening
---------------

At present, many online services are available to search for targets of small-molecule drugs by shape screening. According to whether these services and software programs can directly sort the potential protein targets by probability or not, we classified them into direct target prediction tools, such as SuperPred (Dunkel et al., [@B36]), HitPick (Liu et al., [@B109]), ChemMapper, SEA search server, ReverseScreen3D (Kinnings and Jackson, [@B83]), TarPred (Liu et al., [@B107]), and SwissTargetPrediction, and indirect target prediction tools, such as SwissSimilarity (Zoete et al., [@B212]), ChemProt, TargetHunter (Wang L. et al., [@B173]), CSNAP3D (Lo et al., [@B114]), and ROCS. These categories, respectively, are located on the inside and outside of the outer ring in Figure [3](#F3){ref-type="fig"}. A brief introduction to these services, including their input and output formats, shape similarity calculation methods, database information and website links, is provided in Table [1](#T1){ref-type="table"}. Because indirect target prediction services require the manual selection of protein targets, we do not provide a more detailed overview of these tools here. We chose the SEA search server among the direct target prediction services as a representative for further description because it is the oldest and most widely used shape-screening service (Keiser et al., [@B77]).

As a web-based target prediction tool, SEA was developed in 2007, and it performs quantitative classification and target association based on the chemical similarity of protein-related ligands (Keiser et al., [@B77]). SEA supports only the SMILES format for the input of query molecules for target prediction. After receiving the relevant information about the query compound, SEA performs a pairwise comparison of a 2D similarity metric in a collection of \~65,000 ligands annotated with drug targets, in which most annotations contain hundreds of ligands (Keiser et al., [@B77]). SEA then clusters the ligands based on their chemical similarity into hundreds of sets, relating their corresponding annotated targets to each other quantitatively, and further uses a model resembling that of BLAST (Mount, [@B129]) to link these sets together in a minimal spanning tree (Keiser et al., [@B77]). Next, a statistical model is used to rank the significance (*E*-value) of the resulting similarity scores of each set in the minimum spanning tree. Finally, SEA produces a list of Max Tanimoto coefficients (MaxTc) and *E*-values. A larger similarity score (maxTC) with smaller significance score (*E*-value) indicate a higher rank, and there is a greater probability that the protein is a potential target.

Pharmacophore screening
-----------------------

PharmMapper, the only web server to screen the potential protein targets of a query molecule based on pharmacophore modeling (Figure [3](#F3){ref-type="fig"}), was developed in 2010 (Liu et al., [@B108]; Wang X. et al., [@B176]). PharmMapper uses a triangle hashing mapping method to match the pharmacophore models between the compound and the internal database ligands to predict potential protein targets of a query molecule (Liu et al., [@B108]). A brief introduction to this online tool is also given in Table [1](#T1){ref-type="table"}, including the input and output formats, database information and website link. Its in-house database, PharmTargetDB, will be described in detail in the Databases section. PharmMapper supports the Tripos Mol2, MDL and SDF formats for the input of a 2D or 3D query molecule structure to begin a job. Next, PharmMapper flexibly aligns the molecule with each protein pharmacophore model in its database and calculates the fit score between the query molecule and the pharmacophore models (Liu et al., [@B108]). Subsequently, PharmMapper ranks candidate targets according to the fit score (Liu et al., [@B108]) or according to normalized fit scores standardized by using a two-dimensional Z-transformation algorithm on the ligand and pharmacophore target dimensions (Wang X. et al., [@B175]), and records the aligned pharmacophore pose for the query molecule and targets. With the default setting, the top 300 target hits of the prioritizing list are outputted, and users can select candidate proteins based on both these fit scores and the aligned pose for further bioassay experiments (Liu et al., [@B108]; Wang X. et al., [@B176]).

Reverse docking
---------------

TarFisDock, idTarget, and INVDOCK (Figure [3](#F3){ref-type="fig"}) are three reverse docking programs that are currently widely used in predicting the targets and mechanisms of various active biomolecules. A brief introduction to these tools is given in Table [1](#T1){ref-type="table"}, including the input and output formats, database information and website links. Here, we will also provide a slightly more detailed description of these three tools.

TarFisDock, a web-based tool for predicting the potential binding targets of a given ligand, was first released in 2006 (Li et al., [@B99]) and last updated in 2008 (Gao et al., [@B49]). TarFisDock uses reverse docking to search for all possible protein binding partners of small molecules from a potential drug target database called PDTD (Li et al., [@B99]), which will be described further in the Databases section. This program supports only the mol2 format for the input of the query molecule. TarFisDock (Li et al., [@B99]) uses the docking program DOCK 4.0 to perform molecular docking between the given molecule and each protein in the PDTD, and it calculates their binding energy based on van der Waals and electrostatic interaction terms by using the Amber force field (Weiner et al., [@B182]). TarFisDock can output a list of the top 2, 5, or 10% target hits according to binding energy. The main limitation of TarFisDock is the insufficient number of target proteins in the PDTD. The PDTD initially released in 2006 contained only 698 protein structures (Li et al., [@B99]) and was expanded to contain \>830 protein targets in 2008 (Gao et al., [@B49]). TarFisDock considers the flexibility of the small molecules but has yet to consider the flexibility of the protein targets.

In 2012, the web server idTarget (Wang et al., [@B169]) was developed to predict the potential binding targets of small molecules via a divide-and-conquer reverse docking approach. To improve the efficiency of target prediction, idTarget uses a contraction-and-expansion strategy to differentiate the protein structures at different levels for molecular docking into the families of homologous structures by clustering almost all of the protein structures deposited in the PDB (Wang et al., [@B169]). idTarget supports multiple coordinate formats, including pdbqt and mol2, for the input of the given molecule. Then, the program uses MEDock (Chang et al., [@B14]) to initially generate a large number of conformations of the query molecule and directly orient them inside the grid box of the binding site for molecular docking (Wang et al., [@B169]). Subsequently, idTarget assesses the binding pose by using semi-empirical score functions derived from quantum chemical charge models and robust regression analysis (Wang et al., [@B169]). Finally, the program outputs two sets of results, both of which are ranked in ascending order of the predicted binding free energy (ΔG^Pred^). One set of results is listed according to the names of the proteins, while the other is listed according to the names of the homologous families (Wang et al., [@B169]). In addition, idTarget provides two modes for searching binding poses, scanning mode and fast mode (Wang et al., [@B169]). In "scanning mode," molecular docking is performed individually for each protein structure in the database. In "fast mode," the ligand is docked simultaneously to the binding sites of the superposed homologous protein structures, and the binding poses are further minimized by adaptive local sampling (Shindyalov and Bourne, [@B160]). The fast mode performs quick searches via docking between the ligand and the common binding sites after the protein structures of each homologous family are pre-aligned, but the scanning mode does not limit the docking conformation searches to these predetermined binding sites (Wang et al., [@B169]). Both modes uses the strategy of ensemble docking (Lorber and Shoichet, [@B115]) to consider the flexibility of the receptor indirectly (Wang et al., [@B169]).

INVDOCK (Chen and Zhi, [@B22]), an online service for ligand-protein reverse docking that runs on both Windows and Unix platforms, was developed in 2001. INVDOCK has an in-house protein target database of 9000 protein and nucleic acid entries (Chen and Zhi, [@B22]). It supports standard 3D ligand structure files, such as the SDF and MOL formats. INVDOCK sets cavities on the protein surface that are covered by a large portion of spherical probes as active binding pockets. The automatic docking is performed by multi-configuration shape matching between the molecule and cavities. Then, torsion optimization and energy minimization are performed on the molecule and on the protein residues in the binding region (Chen and Zhi, [@B22]). Finally, the simplified DOCK scoring method is used to score the binding energy, and the protein targets are ranked in ascending order by the ligand-protein interaction energy function (ΔE~LP~; Chen and Zhi, [@B22]). INVDOCK also considers the flexibility of the protein via a limited torsion space sampling of rotatable bonds in the side chains of the target residues at the binding site (Chen and Zhi, [@B22]).

Integrated software suites
--------------------------

Some drug design software suites, such as Schrödinger ([@B156]) and Discovery Studio (BIOVIA, [@B10]), can also be used in shape screening, pharmacophore screening, and reverse docking to predict the protein targets of small molecules.

The Schrödinger modules for reverse screening are "Shape Screening," "Pharmacophore Modeling," and "Docking". However, Schrödinger does not provide any ligand or protein database that can be used for reverse screening, and thus, users must provide the databases themselves. "Shape Screening" and "Pharmacophore Modeling" require a protein-annotated ligand database that can be generated by a simple process from the ligand library Ligand Expo, which can be downloaded from the PDB database (Feng et al., [@B46]; Rose et al., [@B147]). Each small-molecule ligand in this library is annotated with its co-crystallized protein target information. The protein structure grid database for reverse docking can be constructed by users via grid generation by the "Docking" module after the "Protein Presentation Wizard" is used to pre-process the protein crystal structure coordinates from the PDB, such as to remove water molecules and add hydrogens. Then, reverse docking can be performed by using "Glide Cross Docking" to dock a given molecule with multiple proteins simultaneously. Although the number of proteins for simultaneous docking in "Glide Cross Docking" is limited (normally \~ 50), users can write their own scripts to run reverse docking for one ligand and many proteins. We have performed several reverse screening tasks by using these modules in the Schrödinger software package (Kim et al., [@B81]; Lim et al., [@B104]; Wang Z. et al., [@B180]).

The "Pharmacophore" and "Receptor-Ligand Interaction" modules of Discovery Studio can be used for reverse screening. Users can select shape screening or pharmacophore screening by using the "Ligand Profiler" tool in the "Pharmacophore" module. This tool allows users to upload a database or use the Ligand Profiler Pharmacophore Database, PharmaDB, provided in the software. This database is generated from an annotated database of druggable binding sites called scPDB (Desaphy et al., [@B30]) based on the PDB and contains the molecular structure and corresponding pharmacophores for calculation of the shape and pharmacophore similarity. The protein crystal structure database for reverse docking must be prepared by the user. These crystal structures can be defined by the "Define and Edit Binding Site" in the "Tools" menu of the "Receptor-Ligand Interaction" module. "Libdock Batch Mode" in the "Protocols" menu of the "Receptor-Ligand Interaction" module can be used for batch docking and has the same effect as reverse docking. Because of the different algorithms and databases needed, the advantages and disadvantages of these two software suites for reverse screening have yet to be evaluated.

Databases
---------

Databases, whether protein-annotated ligand structure/pharmacophore databases or protein structure grid databases, are key elements of reverse screening. Although reverse screening has been under development for nearly two decades, no general or benchmarked database is available for use in different methods or programs. Here, we have classified the existing relevant databases at different levels (Figure [4](#F4){ref-type="fig"}). The first class of databases is associated with software built by software developers and used for program running. We call these databases "software databases" or "direct databases" (shown at the bottom layer of Figure [4](#F4){ref-type="fig"}). Each database in this class is named for its corresponding software or referred to as the software in-house database. The second class of databases provides resources describing annotated ligands or target structures, but the users must process and collect these resources to construct direct databases for reverse screening. We call these databases "indirect databases" (shown in the middle layer of Figure [4](#F4){ref-type="fig"}), and examples include the PDB (Rose et al., [@B147]) and ZINC (Sterling and Irwin, [@B165]). The third class of databases can provide a large amount of information about ligands or proteins that can be used for reverse screening, but collecting and organizing the information from these databases to construct direct databases is difficult. However, we can use them to search for various information resources, such as additional targets, the bioactivities of matched molecules, or the signaling pathways of potential target proteins for further analysis of the reverse screening results. We call these databases "reference databases" (shown in the upper layer of Figure [4](#F4){ref-type="fig"}); examples include PubChem (Kim et al., [@B82]) and UniProt (Pundir et al., [@B142]). Relevant information on several direct databases used for reverse screening can be found in Table [1](#T1){ref-type="table"}. In addition, information on indirect and reference databases, including the database coverage and website links, is listed in Table [2](#T2){ref-type="table"}. In the following paragraphs, we provide a slightly more detailed introduction to these three classes of databases and their relationships with each other.

![The relationships among direct databases, indirect databases, and reference databases used in reverse screening.](fchem-06-00138-g0004){#F4}

###### 

Characteristics of indirect and reference databases.

  **Database name**        **Aims**                                                                                                                                               **Coverage**                                                                                                                                                       **Website**                                        **Last update**
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------- -----------------
  **INDIRECT DATABASE**                                                                                                                                                                                                                                                                                                                                                                                 
  STITCH                   A database of known and predicted interactions between chemicals and proteins                                                                          9.6 million proteins, 0.5 million chemicals                                                                                                                        <http://stitch.embl.de/>                           2017
  HMDB                     A comprehensive, high-quality, freely accessible online database of small-molecule metabolites found in the human body                                 74,507 metabolite entries, 5,701 protein sequences linked to metabolite entries                                                                                    <http://www.hmdb.ca/>                              2017
  ZINC                     Database of commercially available compounds for virtual screening                                                                                     \>100 million purchasable compounds                                                                                                                                <http://zinc15.docking.org/>                       2015
  ChEMBL                   An open large-scale bioactivity database                                                                                                               2,101,843 compound records, 1,735,442 distinct compounds                                                                                                           <https://www.ebi.ac.uk/chembl/>                    2017
  BindingDB                Database of measured binding affinities                                                                                                                2037 FDA-approved small-molecule drugs, 241 FDA-approved biotech (protein/peptide) drugs, 96 nutraceuticals, \>6000 experimental drugs                             <https://www.bindingdb.org/bind/index.jsp>         2011
  DrugBank                 Database combining detailed drug data with comprehensive drug target information                                                                       8,261 drug entries, 4,338 non-redundant protein sequences                                                                                                          <https://www.drugbank.ca/>                         2017
  PDB                      Crystal structures of macromolecules and ligands                                                                                                       133,093 macromolecular structures, 53,025 citations, 23,711 ligands                                                                                                <http://www.rcsb.org/pdb/home/home.do>             2017
  scPDB                    Druggable binding sites from the PDB                                                                                                                   9283 entries, 3678 proteins, 5608 ligands                                                                                                                          <http://bioinfo-pharma.u-strasbg.fr/scPDB/>        2013
  TTD                      Information on therapeutic protein and nucleic acid targets, relevant diseases, pathway information and the corresponding drugs                        2,589 targets, 31,614 drugs, 20,278 small molecules, 653 antisense drugs                                                                                           <http://bidd.nus.edu.sg/group/cjttd/>              2011
  **REFERENCE DATABASE**                                                                                                                                                                                                                                                                                                                                                                                
  PubChem                  Information on chemical substances and their biological activities                                                                                     \>235 million substance descriptions, 90 million unique chemical structures, 230 million bioactivity outcomes from over one million biological assay experiments   <https://pubchem.ncbi.nlm.nih.gov/>                2017
  CHEBI                    A database and ontology of molecular entities focused on "small" chemical compounds                                                                    \>52,450 compounds                                                                                                                                                 <http://www.ebi.ac.uk/chebi/>                      2017
  UniProt                  Resource for protein sequences and functional information                                                                                              Swiss-Prot (555,100), TrEMBL (88,032,926)                                                                                                                          <http://www.uniprot.org/>                          2017
  PDSP Ki database         A unique resource in the public domain that provides information on the abilities of drugs to interact with an expanding number of molecular targets   60,231 annotated ligands                                                                                                                                           <https://kidbdev.med.unc.edu/databases/kidb.php>   2017

Direct databases
----------------

### Direct databases used in shape screening

Each online service for shape screening has its own in-house database, except ROCS (Rush et al., [@B149]), which requires users to prepare their own protein-annotated ligand databases (Mori et al., [@B127]). The database information for 12 shape-screening software programs is shown in the "coverage" column of Table [1](#T1){ref-type="table"}. Among the 11 direct databases, TargetHunter, CSNAP3D and ReverseScreen3D do not give specific capacity data; for the former two, the information is not published, and the latter is noted only as updated with updates to the RCSB PDB, according to the literature (Kinnings and Jackson, [@B83]).

Figure [4](#F4){ref-type="fig"} shows 10 direct databases with clear sources, including HitPick, CSNAP3D, TargetHunter, SwissTargetPrediction, SuperPred, SwissSimilarity, ChemProt, ChemMapper, SEA, and ReverseScreen3D. These databases are basically constructed by extracting data from indirect databases (Figure [4](#F4){ref-type="fig"}). For example, ChemMapper is built from several public databases, including ChEMBL (Gaulton et al., [@B50]), DrugBank (Law et al., [@B93]), BindingDB (Gilson et al., [@B55]), KEGG (<http://www.kegg.jp/kegg/>) and the PDB. It collects bioactive targets and pharmacological information on small molecules, each of which has various pre-generated conformations for 3D similarity screening (Gong et al., [@B59]). ChemProt 3.0 (Kringelum et al., [@B87]) includes all chemical-protein interaction data from the available open source databases, including ChEMBL (version 19), BindingDB, the Psychoactive Drug Screening Program (PDSP) Ki database (Roth et al., [@B148]), and DrugBank, as well as clinical information from the Anatomical Therapeutic Chemical (ATC) Classification System (Wang Y. C. et al., [@B178]) and side effect data from Sider (Kuhn et al., [@B89]). The SwissSimilarity database gathers protein-annotated ligands mainly from four indirect databases, namely, HMDB (Wishart et al., [@B184]), ZINC, ChEMBL, and DrugBank, as well as from some reference databases, such as Chemical Entries of Biological Interest (ChEBI; Hastings et al., [@B66]). The SuperPred (Nickel et al., [@B132]) database consists of a large data set of ligand-target interactions from two indirect databases, ChEMBL and BindingDB. The CSNAP3D (Lo et al., [@B114]), Target Hunter (Wang L. et al., [@B173]), SwissTargetPrediction (Gfeller et al., [@B53]), and SEA (Keiser et al., [@B77]) databases are all constructed by taking ligands with protein target information from ChEMBL. The HitPick (Liu et al., [@B109]) database collects information from the STITCH database (Szklarczyk et al., [@B167]), and the information in ReverseScreen3D (Kinnings and Jackson, [@B83]) is extracted from the PDB database. In addition, the TarPred (Liu et al., [@B107]) database, which is not shown in Figure [4](#F4){ref-type="fig"}, is a compound-target-disease database built by gathering information from the Comparative Toxicogenomics Database (CTD; Davis et al., [@B29]) and UniProt.

### Direct databases used in pharmacophore screening

Two direct databases used for pharmacophore screening are shown in Figure [4](#F4){ref-type="fig"}. PharmTargetDB is the in-house database of the PharmMapper server (Liu et al., [@B108]), and PharmaDB (Meslamani et al., [@B126]) is the direct database deposited and used in Discovery Studio. Since these two databases are updated when the software updates, the different versions of PharmTargetDB and PharmaDB have different data capacities. The numbers of pharmacophore models in the newest versions are also shown in Table [1](#T1){ref-type="table"}.

The pharmacophore models in PharmTargetDB are derived from the DrugBank, BindingDB, PDB, and PDTD databases. These models are built by extracting pharmacophore features within cavities by using the receptor-based pharmacophore modeling program Pocket 2.0 (Chen and Lai, [@B16]) after the binding sites of given protein structures are detected and ranked based on their druggability scores by using the software CAVITY (Yuan et al., [@B197]) for binding site detection (Wang X. et al., [@B176]). The original version of PharmTargetDB contained more than 7,000 pharmacophore models built from co-crystallized complex structures of protein targets (Liu et al., [@B108]). A new version of PharmMapper was published in 2017 (Wang X. et al., [@B176]), and the new PharmTargetDB is six times larger than the previous one, with a total of 23,236 proteins covering 51,431 pharmacophore models. PharmaDB is the pharmacodynamics database for Discovery Studio drug design software, and its pharmacophore models are constructed by using the Receptor-Ligand Pharmacophore Generation Protocol with default settings based on the binding information of ligand and protein complexes in the scPDB database. The original version of PharmaDB contained 68,056 pharmacophore models annotated with receptor information (Meslamani et al., [@B126]). The latest version of PharmaDB includes 140,000 pharmacophore models (BIOVIA, [@B10]), and users can utilize it in Discovery Studio to perform rapid reverse pharmacophore screening to search for protein targets of small molecules.

### Direct databases used in reverse docking

The direct databases used in reverse docking are collections of target structure grids, which are usually generated from protein crystal structures by using docking programs or their auxiliary software tools. Before grid generation, the target crystal structures downloaded from the PDB must be preprocessed to remove ions and waters, add hydrogens and define the binding pocket. The original 3D protein structures can also be downloaded from some PDB derivative databases, such as the PDBbind-CN Database (Liu Z. et al., [@B113]), where all valid ligand-protein structures in the PDB are identified and collected.

PDTD, INVDOCK, and idTarget are the three direct databases used for reverse docking shown in Figure [4](#F4){ref-type="fig"}. Among them, PDTD is the only open database, and it can be downloaded as a compressed file, which is then decompressed as a collection of two types of structure files. The first type is the preprocessed protein structure file in the PDB and mol2 formats, and the second type is the active site structure file in PDB format. These two types of structure files for any PDB entry can be downloaded independently and viewed using the molecular visualization tool plug-in (Gao et al., [@B49]). Currently, this database contains more than 1,100 protein entries with 3D structures in the PDB and covers 841 diverse drug targets associated with diseases, biological functions, and signaling pathways (Gao et al., [@B49]). The binding (active) sites of these protein structures were defined by a data set of amino acid residues within 6.5 Å of the bound ligand (Gao et al., [@B49]). The INVDOCK and idTarget databases are not published but are the in-house databases of the corresponding programs. In addition, in contrast to the binding sites defined by the co-crystallized ligands in the PDTD, the binding sites in the INVDOCK and idTarget databases are generated from the available cavities by a search performed with spherical probes. The protein structures in these two databases also originate from the PDB. The INVDOCK in-house database, constructed in 2001, collects 9000 proteins and nucleic acid structures from the PDB database (Chen and Zhi, [@B22]). Each receptor structure grid in this database is constructed by first calculating the inward-facing surface covering the interface of van der Waals surfaces of the receptor crystal structure with a probe sphere 1.4 Å in radius. The binding site is then defined as the surrounding space within 15 Å of the center of the cavity formed by the combination of neighboring spheres covered by protein atoms in more than 50% of directions. Finally, grid generation is performed (Chen and Zhi, [@B22]). The idTarget database collects all protein structures in the PDB and is regularly updated when the PDB updates (Wang et al., [@B169]). The binding sites of each protein in the database are dynamically determined, and the grids are constructed by the "divide-and-conquer" method according to the size of the query molecule (Wang et al., [@B169]). Theoretically, idTarget could be the most extensive and complete database among the three for reverse docking.

### Indirect databases

Indirect databases are rich in ligand and target information and can be simply processed to build direct databases for reverse screening. Nine indirect databases are shown in the middle layer of Figure [4](#F4){ref-type="fig"}, and a brief introduction to these databases, including the coverage, update time and website link, is given in Table [2](#T2){ref-type="table"}. Among these nine indirect databases, ZINC, ChEMBL, BindingDB, and DrugBank mainly include structural information on ligands and their target annotations, whereas the PDB, scPDB, and Therapeutic Target Database (TTD) mainly provide 3D structures of proteins with ligand binding information. The 15 direct and in-house software-associated databases used for reverse screening are essentially extracted or constructed from these indirect databases. These indirect databases are also extensively linked to reference databases. For example, DrugBank and ChEMBL have mutual data exchange with PubChem, ChEBI, and UniProt. BindingDB (Gilson et al., [@B55]) collects data from the PubChem and PDSP Ki databases. The scPDB and PDB share protein information with UniProt, including sequences and crystal structures. In addition, HMDB (Wishart et al., [@B185]) and ZINC share compound information with ChEBI, and the TTD database collects its information on therapeutic protein targets from UniProt.

Users can employ indirect databases to build their own databases when they use large commercial software suites for molecular drug design, such as Schrödinger and Discovery Studio, to perform reverse screening. For example, users can collect small molecules with explicit target annotation from the DrugBank, ChEMBL, and ZINC databases to construct a ligand database for shape screening. They can also use ligand-protein binding information from the BindingDB, scPDB, and PDB databases to build a pharmacophore model database for pharmacophore screening or a protein structure grid database for reverse docking. Notably, Ligand Expo (Feng et al., [@B46]) from the PDB can be easily used to build in-house program databases for shape or pharmacophore screening after non-ligand small molecules, including metal ions and solvent molecules, are removed. In addition, a collection of protein crystal structures downloaded from the PDB can be used to generate a protein structure grid database for reverse screening. In fact, we built our own databases for use in Schrödinger based on this Ligand Expo database and the protein structures in the PDB, and we then performed shape screening and reverse docking to search for the protein targets of several natural compounds (Kim et al., [@B81]; Lim et al., [@B104]; Wang Z. et al., [@B180]).

### Reference databases

Reference databases normally contain a very large amount of information on small-molecule compounds and proteins. However, extracting the rich information resources from these databases to establish direct databases for reverse screening can be difficult for users. Nevertheless, we can utilize these databases to search for additional information on the matched molecules and their potential protein targets from reverse screening results.

The four main reference databases, PubChem, ChEBI, PDSP Ki, and UniProt, which are closely associated with the nine indirect databases, are shown in the upper layer of Figure [4](#F4){ref-type="fig"}. A brief introduction to these four databases is also provided in Table [2](#T2){ref-type="table"}. PubChem consists of three interrelated sub-databases: substances, compounds, and bioassays. The first two sub-databases provide information on the chemical structure and other properties of small molecules, and the sub-database of bioassays gives information on their pharmacological properties and biological targets (Kim et al., [@B82]). ChEBI is a freely available dictionary of molecular entities focused on "small" chemical compounds. ChEBI and ChEMBL are both sites of the European Molecular Biology Laboratories, and their data occasionally overlap. Compared with ChEMBL, ChEBI is more focused on "molecular entity" information, such as the chemical and biological roles and applications of a small molecule, rather than on biological target information (Hastings et al., [@B65], [@B66]). The PDSP Ki database is a unique open resource that provides information on the ability of drugs to interact with increasing numbers of molecular targets. The key data in this database are the Ki activity data on ligands internally derived or from published articles, but it also includes information on protein-annotated ligand structures, protein-ligand affinities, and article sources (Roth et al., [@B148]). UniProt (Pundir et al., [@B142]) is a freely accessible resource of protein sequence and function information extracted from gene sequencing and published literature that undergoes quality assurance by curator-evaluated computational analysis (Poux et al., [@B139]).

The PubChem, ChEBI, UniProt, and Ki databases are the four major reference databases used by researchers. However, more reference databases containing information on proteins or ligands are available, and readers who are interested in learning about them can read two further database review papers authored by Zhang Y. et al. ([@B204]) and Moura Barbosa and Del Rio ([@B130]).

Applications
------------

We reviewed nearly all articles on the applications of shape, pharmacophore screening and reverse docking in searching for the potential targets of small molecules published since 2000 and conducted a systematic analysis. In addition, we have provided slightly more detailed descriptions of some representative examples of the application of existing services to drug discovery. In reviewing these previous studies, we found two approaches to method application: the use of a single method and the use of combined methods. In general, shape screening, pharmacophore screening and reverse docking have all been successfully applied individually. However, these methods have their own limitations in terms of features and application scopes, as mentioned above. The majority of newer examples involve the combined application of multiple methods. Finally, it is noted that all the compounds as examples for illustration in this section are shown in Figure [1](#F1){ref-type="fig"}.

Shape screening
---------------

Shape-screening services have a wide range of applications. Table [3](#T3){ref-type="table"} shows 18 examples of the use of SEA, TargetHunter, ROCS, SwissTargetPrediction, etc. to perform shape screening for molecular target prediction. Here, even if an article involves several query molecules, we still present them as one example.

###### 

Applications of shape screening in predicting protein targets of small molecules.

  **Query molecule**                                            **Target information**                                 **Reverse screening tool**   **References**
  ------------------------------------------------------------- ------------------------------------------------------ ---------------------------- --------------------------
  **EXPERIMENTALLY VERIFIED**                                                                                                                       
  Prozac^1^, Vadilex^2^, Rescriptor^3^                          β1 receptor^1^, 5-HT transporter^2^, HRH4^3^           SEA                          Keiser et al., [@B78]
  Wuweizi (compound 11/12)                                      GBA3^11,\ 12^, SHBG^11,\ 12^                           SEA                          Wang et al., [@B170]
  Lignan                                                        5-HT1AR                                                SEA                          Zheng et al., [@B210]
  Plumbagin                                                     TrxR, GR\'                                             SEA                          Hwang et al., [@B72]
  Obacunone                                                     MIF                                                    SEA                          Gao et al., [@B48]
  5-aza-dC                                                      HDM2                                                   SuperPred                    Putri et al., [@B143]
  Sini decoction (aconitine^1^, liquiritin^2^, 6-gingerol^3^)   ADRB1^1^, ACE^2^, HMGCR^1,\ 3^                         TargetHunter                 Zhang H. et al., [@B202]
  Salvinorin A[^\*^](#TN1){ref-type="table-fn"}                 OPRK, CB1, CB2, DRD2                                   TargetHunter                 Xu et al., [@B188]
  **NOT EXPERIMENTALLY VERIFIED**                                                                                                                   
  NBP                                                           NQO1, IDO, NADH-ubiquinone oxidoreductase              SEA                          Wang Y. et al., [@B179]
  Quinoline derivative (83b1)                                   PPARδ                                                  SEA                          Pun et al., [@B141]
  Tributyltin (Ch-409)                                          RamC                                                   SwissTargetPrediction        Waseem et al., [@B181]
  Xeronine                                                      Adr A3, TDP1, muscleblind-like proteins 1              SwissTargetPrediction        Sanni et al., [@B151]
  **KNOWN TARGETS COMPUTATIONALLY VERIFIED**                                                                                                        
  Methadone^1^, emetine^2^, loperamide^3^                       Muscarinic M3^1^, α2 adrenergic^2^, NK2 receptors^3^   SEA                          Keiser et al., [@B77]
  CID 46907796                                                  Nrf2                                                   TargetHunter                 Wang L. et al., [@B173]
  Chlorotrianisene                                              COX-1, ESR1                                            SwissTargetPrediction        Gfeller et al., [@B53]
  Entecavir                                                     POLB                                                   TarPred                      Liu et al., [@B107]
  Taxol mimetics                                                Tubulin                                                CSNAP3D                      Lo et al., [@B114]
  Caffeine                                                      D2R                                                    ChemProt                     Kringelum et al., [@B87]

*Target prediction confirmed by the literature. Superscript values denotes that the protein targets in the second column correspond to the query molecules in the first column respectively*.

Reverse screening based on shape similarity has multiple types of applications. First, it is used to search for the targets of molecules from Chinese herbal medicine. For instance, using TargetHunter, Zhang et al. predicted human beta-1 adrenergic receptor (ADRB1) as the protein target of aconitine (compound **3**), an experimentally active component of Sini Decoction in the treatment of cardiovascular disease, and this prediction has been experimentally verified (Zhang H. et al., [@B202]). Shape screening is also helpful for drug repositioning and for clarifying the mechanisms of action of existing drugs. For example, Keiser et al. conducted shape screening using SEA to reposition 3,665 FDA-approved and investigational drugs, and they successfully predicted unintended targets of several drugs, such as the antagonism of the β1 receptor by the transporter inhibitor prozac (compound **4**), the inhibition of the 5-HT transporter by the ion channel drug vadilex (compound **5**), and the antagonism of the histamine H4 receptor by the enzyme inhibitor rescriptor (compound **6**; Keiser et al., [@B78]).

Pharmacophore screening
-----------------------

Reverse screening based on pharmacophore modeling is also widely used to search for the targets of components of various Chinese traditional medicines. Table [4](#T4){ref-type="table"} shows 27 examples of the use of PharmMapper and Discovery Studio to perform pharmacophore screening for the prediction of molecular targets.

###### 

Applications of pharmacophore screening in predicting protein targets of small molecules.

  **Query molecule**                                                    **Target information**                     **Reverse screening tools**   **References**
  --------------------------------------------------------------------- ------------------------------------------ ----------------------------- -----------------------------------
  **EXPERIMENTALLY VERIFIED**                                                                                                                    
  CT                                                                    MAP2K1                                     PharmMapper                   Yuan et al., [@B196]
  Arctigenin                                                            PDK1                                       PharmMapper                   Fang et al., [@B43]
  HSYA                                                                  XO                                         PharmMapper                   Xu et al., [@B187]
  ZYZ-488                                                               Apaf-1                                     PharmMapper                   Wang Y. et al., [@B177]
  NCI 748494/1                                                          c-Met kinase                               PharmMapper                   El-Wakil et al., [@B39]
  UA                                                                    CASP-3, JNK2, ERK1                         PharmMapper                   Ma et al., [@B122]
  BBR                                                                   GR, p38, DHODH                             PharmMapper                   Liu et al., [@B105]
  5,7-dihydroxy-4′-methoxy-8-prenylflavanone                            AChE                                       PharmMapper                   Das et al., [@B28]
  Phytoestrogens (genistein^1^, daidzein^2^, secoisolariciresinol^3^)   AKR1B1^1^, H-Ras^2^, GSTP1^3^              PharmMapper                   Dutta et al., [@B38]
  **NOT EXPERIMENTALLY VERIFIED**                                                                                                                
  MCDF                                                                  GR                                         PharmMapper                   Chitrala and Yeguvapalli, [@B24]
  Capsaicin                                                             CA2                                        PharmMapper                   Ye et al., [@B193]
  SID 242078875                                                         DPP-IV, PTP1B, PEPCK, GSK-3B, GK           PharmMapper                   Krishnasamy and Muthusamy, [@B88]
  Flavanoid analogs                                                     CDK2                                       PharmMapper                   Simon et al., [@B162]
  Chalcones and chalcone-like compounds                                 Cysteine proteases                         PharmMapper                   Gomes et al., [@B58]
  16E-arylideno-nitrogen mustard hybrids(3/4)                           GRs                                        PharmMapper                   Acharya et al., [@B1]
  Components of CO                                                      ESR1, ESR2, HSD11B1, cortisone reductase   PharmMapper                   Wang N. et al., [@B174]
  N-substituted tetrahydro-β-carboline imidazolium salt derivatives     MEK-1                                      PharmMapper                   Liang et al., [@B103]
  ASC                                                                   AKR1B1, ALB, AR, BACE1, CDK2, F2           PharmMapper                   Zeng et al., [@B200]
  GFW compounds                                                         F2, MMP3, CA2, AKR1B, CDK2                 PharmMapper                   Zeng et al., [@B201]
  Thiadiazole compounds                                                 c-Met                                      PharmMapper                   Meshram et al., [@B125]
  Components in SFJD                                                    Multi-targets in ERK pathway               PharmMapper                   Li et al., [@B102]
  Isoquinoline alkaloids                                                MIF, ZipA-FtsZ, GAPDH, etc.                Discovery Studio 3.5          Lei et al., [@B96]
  Six GTs                                                               GCN5, CDK2                                 Discovery Studio 4.0          Shao et al., [@B159]
  Pinctada fucata oligopeptide                                          5HT2A, BACE-1                              Discovery Studio              Chen et al., [@B20]
  **KOWN TARGETS COMPUTATIONALLY VERIFIED**                                                                                                      
  Tamoxifen                                                             ERRγ                                       PharmMapper                   Liu et al., [@B108]
  S-adenosyl-L-homocysteine                                             Modification methylase TaqI                PharmMapper                   Wang X. et al., [@B175]
  Kanamycin                                                             APH(2′)-Iva                                PharmMapper                   Wang X. et al., [@B176]

*^\*^ Target prediction confirmed by the literature. Superscript values denotes that the protein targets in the second column correspond to the query molecules in the first column respectively*.

For example, Liu et al. used PharmMapper to predict p38, glucocorticoid receptor (GR) and dihydroorotate dehydrogenase (DHODH) as potential targets of berberine (BBR, compound **7**) and further elucidated the possible molecular mechanisms by which these protein targets participate in the anti-melanoma activity of BBR (Liu et al., [@B105]). Lei et al. employed the Pharmacophore module of Discovery Studio 3.5 in reverse screening and found that the isoquinoline alkaloids (such as compound **8**) extracted from Macleaya cordata (Bo Luo Hui) might target macrophage migration inhibitory factor (MIF), potentially leading to the broad-spectrum antitumor effects of the plant (Lei et al., [@B96]).

Reverse docking
---------------

Reverse screening based on molecular docking is widely used to search for the targets of small molecules to elucidate their mechanisms of action. Tables [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"} show 25 and 20 examples with and without experimental validation, respectively, of the application of reverse docking to the prediction of molecular targets by using TarFisDock, idTarget, INVDOCK, and conventional virtual screening software such as DOCK, MDock, and AutoDock.

###### 

Applications of reverse docking in predicting protein targets of small molecules with experimental verification.

  **Query molecule**                                             **Target information**               **Reverse screening tools**   **References**
  -------------------------------------------------------------- ------------------------------------ ----------------------------- -----------------------------
  Triptonide^1^, triptolide^2^, triptriolide^3^                  ERα^1,\ 2,\ 3^                       AutoDock 4.2                  Liu et al., [@B110]
  c-di-GMP                                                       Human LCN2 protein                   DOCK 6                        Li et al., [@B101]
  Derivatives of indirubin (6BIO)                                PDK1                                 GlamDock                      Zahler et al., [@B199]
  DAPH                                                           Hexokinase                           GOLD                          Da Matta et al., [@B27]
  Apple polyphenols                                              GMP reductase, GTPase H-ras, HGPRT   idTarget                      Scafuri et al., [@B153]
  Anti-HIV drugs (Pis, NRTIs)[^\*^](#TN2){ref-type="table-fn"}   POLB, TOP1, etc.                     INVDOCK                       Ji et al., [@B75]
  Analgesics[^\*^](#TN2){ref-type="table-fn"}                    ErbB-2, PLA2, GSH-S                  INVDOCK                       Pan et al., [@B134]
  GAD                                                            EphA7, EB1, PRDX3                    INVDOCK                       Yue et al., [@B198]
  BBR                                                            p53                                  INVDOCK                       Lu et al., [@B116]
  SB                                                             EGFR                                 INVDOCK                       Feng et al., [@B45]
  BBR                                                            HSPA8, ANXA5                         INVDOCK                       Lu et al., [@B117]
  AGS-IV                                                         CN, ACE, JNK                         INVDOCK                       Zhao et al., [@B207]
  SB[^\*^](#TN2){ref-type="table-fn"}                            ACE, REN                             INVDOCK                       Ye et al., [@B192]
  WB                                                             CDK2, PAK4, BRaf1                    INVDOCK                       Zhang et al., [@B205]
  BBR                                                            CaM                                  INVDOCK                       Ma et al., [@B121]
  Ophiobolin O                                                   GSK3β                                INVDOCK                       Lv et al., [@B119]
  PRIMA-1                                                        OSC                                  Mdock                         Grinter et al., [@B61]
  Meranzin                                                       COX1, COX2, PPARγ                    SELNERGY                      Do et al., [@B33]
  Tofisopam                                                      PDE4                                 SELNERGY                      Bernard et al., [@B7]
  Anti-*Helicobacter pylori* drugs (compound 1/2)                HpPDF^1,\ 2^                         TarFisDock                    Cai et al., [@B11]
  \[6\]-gingerol                                                 LTA4H                                TarFisDock                    Jeong et al., [@B74]
  5 of 19 natural products                                       DPP-IV                               TarFisDock                    Zhang S. et al., [@B203]
  Bezafibrate                                                    CDK2                                 TarFisDock                    Liu et al., [@B112]
  Bicyclol                                                       IMPDHII                              TarFisDock                    Zhang Y. W. et al., [@B206]
  Esculentoside A                                                CK2                                  TarFisDock                    Li Y. et al., [@B98]

*Target prediction confirmed by the literature. Superscript values denotes that the protein targets in the second column correspond to the query molecules in the first column respectively*.

###### 

Applications of reverse docking in predicting protein targets of small molecules without experimental verification.

  **Query molecule**                                                                                 **Target information**                                                               **Reverse screening tool**   **Reference**
  -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------- -------------------------------
  **NOT EXPERIMENTALLY VERIFIED**                                                                                                                                                                                      
  Tea polyphenols                                                                                    LTA4 hydrolase                                                                       Autodock, TarFisDock         Zheng et al., [@B209]
  4 compounds                                                                                        PBP4                                                                                 Autodock Vina                Sarangi et al., [@B152]
  Lenalidomide                                                                                       VEGFR-2, erbB-3, FGFR-4, ABL, p38MAPK, MMP-3                                         Autodock                     Hu et al., [@B68]
  Torcetrapib                                                                                        PDGFR, HGFR, IL-2, ErbB1                                                             Discovery Studio             Fan et al., [@B42]
  Melamine and cyanuric acid                                                                         GPX1, HEXB, LDH, lys C                                                               INVDOCK                      Ma et al., [@B120]
  PAs                                                                                                GSTA1, GPX1                                                                          INVDOCK                      Yan et al., [@B189]
  Icariin                                                                                            PI3K, AChE                                                                           INVDOCK                      Cui et al., [@B26]
  Dioscin                                                                                            TOP1                                                                                 MDock                        Yin et al., [@B195]
  Ginsenosides                                                                                       MEK1, EGFR, thrombin, Aurora A                                                       Schrödinger                  Park and Cho, [@B135]
  TCDD                                                                                               MMP8, MMP3, OSC, MPO                                                                 TarFisDock                   Oliveroverbel et al., [@B133]
  Ganoderic acid                                                                                     HIV-1 proteasein                                                                     TarFisDock                   Akbar and Yam, [@B2]
  Fullerene derivatives                                                                              HPRT, BACE1                                                                          TarFisDock                   Gupta et al., [@B62]
  Alpha lipoic acid                                                                                  LTA4 hydrolase, VGKC                                                                 TarFisDock                   Maldonado-Rojas, [@B124]
  Aryl-aminopyridine derivatives                                                                     CDK2, aurora kinase, KIT receptor                                                    TarFisDock                   Erić et al., [@B40]
  **KNOWN TARGETS COMPUTATIONALLY VERIFIED**                                                                                                                                                                           
  4-HT, vitamin E                                                                                    ER, GST                                                                              INVDOCK                      Chen and Zhi, [@B22]
  ASA^1^, gentamicin^2^, ibuprofen^3^, IDV^4^, neomycin^5^, penicillin G^6^, 4-HT^7^, vitamin C^8^   Antithrombin^1^, CA1^2,\ 5^, SULT1E1^3^, IFABP^4^, GST^6^, ADH^7^, alphaamylase^8^   INVDOCK                      Chen and Ung, [@B21]
  Biotin^1^, 4-HT^2^, HDPR^3^, methotrexate^4^                                                       Streptavidin^1^, ERa^2^, ADA^3^, DHFR^4^                                             GOLD                         Paul et al., [@B137]
  ε-viniferin                                                                                        PDE4                                                                                 SELNERGY                     Do et al., [@B34]
  Vitamin E^1^, 4-HT^2^                                                                              AChE^1^, DHFR^2^                                                                     TarFisDock                   Li et al., [@B99]
  DRV^1^, 6BIO^2^, N-(4-aminobiphenyl-3-yl)-benzamide^3^                                             HDAC2^1^, HIV-1 PR^2^, CDK2^3^                                                       idTarget                     Wang et al., [@B169]

*^\*^ Target prediction confirmed by the literature. Superscript values denotes that the protein targets in the second column correspond to the query molecules in the first column respectively*.

For example, several research groups used INVDOCK to predict that p53 (Lu et al., [@B116]), calmodulin (CaM; Ma et al., [@B121]), annexin A5 (ANXA5) and heat shock protein family A member 8 (HSPA8; Lu et al., [@B117]) might be protein targets of the broad-spectrum anticancer drug BBR (compound **7**). Zhang et al. employed TarFisDock in the reverse docking of 19 compounds extracted from the traditional Chinese medicines Bacopa monnieri (L.) Wettst and Daphne odora Thunb. Var. Marginata, and they concluded that five of the compounds (such as compound **9**) might target dipeptidyl peptidase IV (DPP-IV), thus accounting for the effectiveness of these medicines in the treatment of diabetes and their anti-inflammatory effects (Zhang S. et al., [@B203]). Scafuri et al. ([@B153]) applied idTarget to predict that the proteins guanosine triphosphatase (GTPase), guanosine 5′-monophosphate oxidoreductase (GMP reductase) and hypoxanthine-guanine phosphoribosyltransferase (HGPRT) might be key targets of apple polyphenols (such as compound **10** and **11**), resulting in their cancer-preventive effects. Grinter et al. used MDock to fish for the protein targets of the compound PRIMA-1 (compound **12**) in the PDTD database and discovered that PRIMA-1 could inhibit the cholesterol synthetic pathway by directly binding with oxidosqualene cyclase (OSC), considerably reducing the viability of BT-474 and T47-D breast cancer cells (Grinter et al., [@B61]).

Hybrid applications
-------------------

The combinations of methods include shape screening with reverse docking, shape screening with pharmacophore screening, pharmacophore screening with reverse docking, and the combination of all three methods. Table [7](#T7){ref-type="table"} shows 22 examples of the use of these four combinations to predict molecular targets.

###### 

Applications of hybrid screening in predicting protein targets of small molecules.

  **Query molecule**                                                         **Target information**            **Method**   **Reverse screening tool**     **References**
  -------------------------------------------------------------------------- --------------------------------- ------------ ------------------------------ -------------------------------------
  **EXPERIMENTALLY VERIFIED**                                                                                                                              
  Rosemary components (carnosol,CA,UA,RA)[^\*^](#TN3){ref-type="table-fn"}   CDK2, MAPK-14, AR\', PPARγ        RD&PS        PharmMapper, idTarget          Deshmukh et al., [@B31]
  DIP[^\*^](#TN3){ref-type="table-fn"}                                       DPD, Bub1                         RD&PS        PharmMapper, idTarget          Ge et al., [@B52]
  *Magnaporthe oryzae* inhibitor C1                                          CYP450, NMT, GS, CHS              RD&PS        PharmMapper, TarFisDock        Chen et al., [@B15]
  SAA[^\*^](#TN3){ref-type="table-fn"}                                       AR                                RD&PS        DRAR-CPI, PharmMapper          Chen and Cui, [@B18]
  Curcumin                                                                   CDK2                              RD&SS        Schrödinger                    Lim et al., [@B104]
  Naproxen                                                                   PI 3-K                            RD&SS        Schrödinger                    Kim et al., [@B81]
  GV2--20                                                                    CA2                               RD&SS        ROCS, AutoDock                 Mori et al., [@B127]
  Kinetin                                                                    Chitinase                         RD&SS        idTarget, ReverseScreen3D      Kumar et al., [@B90]
  Glabridin                                                                  Braf, MEK1/2                      RD&SS        Schrödinger                    Wang Z. et al., [@B180]
  Macrocyclic amidinoureas                                                   Chitinase                         RD&SS        ROCS, OEDocking                Maccari et al., [@B123]
  α-FMH                                                                      GST                               PS&SS        PharmMapper, ReverseScreen3D   Considine et al., [@B25]
  Baicalein                                                                  COMT, MAO-B                       RD&PS&SS     Schrödinger, ReverseScreen3D   Gao et al., [@B47]
  **NOT EXPERIMENTALLY VERIFIED**                                                                                                                          
  Saffron bioactive ingredients (picrocrocin)                                HSP 90-α                          RD&PS        PharmMapper, idTarget          Bhattacharjee et al., [@B9]
  Danshensu                                                                  GTPase Hras                       RD&PS        PharmMapper, idTarget          Chen and Ren, [@B19]
  Tanshinone IIA                                                             RARα                              RD&PS        PharmMapper, AutoDock Vina     Chen, [@B17]
  2-thiazolylimino-5-benzylidin-thiazolidin-4-one                            COX2, AChE, AR, THRα              RD&PS        PharmMapper, TarFisDock        Iyer et al., [@B73]
  Glycopentalone                                                             CDK-2, VEGFR-2                    RD&PS        AutoDock4.2, PharmMapper       Gurung et al., [@B63]
  PGS^1^, PLMF1^2^, 67DiOHC8S^3^                                             GSTA1^1^, PTPNT1^2,\ 3^, CBS^3^   RD&PS        PharmMapper, DRAR-CPI          Pereira et al., [@B138]
  Oxindole pentacyclic alkaloids                                             DHFR, MDM2                        RD&SS        TarFisDock, ReverseScreen3D    Kozielewicz et al., [@B86]
  Quercetin                                                                  PARP1                             RD&SS        SHAFTS, idTarget               Carvalho et al., [@B12]
  Cardamom bioactive components (eucalyptol)                                 CASP-3, PKA                       PS&SS        PharmMapper, ReverseScreen3D   Bhattacharjee and Chatterjee, [@B8]
  Amai alkaloid and pyridine derivatives in maca                             AR\', CA2, ERα, MAPK14, etc.      PS&SS        Discovery Studio4.5            Yi et al., [@B194]

*Target prediction confirmed by the literature. Superscript values denotes that the protein targets in the second column correspond to the query molecules in the first column respectively*.

Eight target prediction examples were performed by combining shape similarity and molecular docking. Kozielewicz et al. employed ReverseScreen3D and TarFisDock to predict the targets of oxindole pentacyclic alkaloids (such as compound **13**) and found that the biological ability of these compounds to induce cancer cell apoptosis may potentially involve the inhibition of several important targets, including dihydrofolate reductase (DHFR) and mouse double minute 2 homolog (MDM2; Kozielewicz et al., [@B86]). The combination of shape screening and pharmacophore screening has been applied in three instances to predict molecular targets. Biplab Bhattacharjee and Jhinuk Chatterjee used PharmMapper and ReverseScreen3D to perform reverse screening and demonstrated that eucalyptol (compound **14**), the effective component of cardamom, might target CASP-3 and cAMP-dependent protein kinase (PKA), resulting in its anti-apoptosis, anti-inflammation, anti-proliferation, anti-invasion and anti-angiogenesis activities in cancer prevention (Bhattacharjee and Chatterjee, [@B8]). The combination of pharmacophore modeling and reverse docking has been used most frequently to predict the targets of small molecules, as shown by the 10 applications given in Table [7](#T7){ref-type="table"}. For example, Ge et al. used PharmMapper and idTarget in reverse screening and predicted that dihydropyrimidine dehydrogenase (DPD) and human spindle checkpoint kinase Bub1 were the potential unintended or secondary targets of the antithrombotic agent dipyridamole (DIP, compound **15**), resulting in its anti-cancer activity (Ge et al., [@B52]). Finally, one application combined all three methods for reverse screening. Gao et al. used the Pharmacophore Modeling and Docking modules in Schrödinger as well as RerverseScreen3D jointly to predict molecular targets and found that baicalein (compound **16**), an anti-Parkinson disease drug, played a protective role in the nervous system by targeting catechol-O-methyltransferase (COMT) and monoamine oxidase B (MAO-B); these targets were confirmed experimentally (Gao et al., [@B47]).

Discussion {#s3}
==========

Comparison of the applications of the three types of reverse screening software and online services in the prediction of small-molecule targets
-----------------------------------------------------------------------------------------------------------------------------------------------

To provide a better understanding of the application of reverse screening for small-molecule target prediction, we collected as many reverse screening tools and databases as possible, most of which have been updated since 2016 (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). In addition, we counted the number of applications of these three methods since 2000, the number of applications of their representative software programs, and the application trends over the years. All information is shown in Tables [3](#T3){ref-type="table"}--[7](#T7){ref-type="table"} and Figures [5A,B](#F5){ref-type="fig"}.

![The number and trend of applications using the three reverse screening methods and representative software since the year 2000.](fchem-06-00138-g0005){#F5}

Different types of reverse screening tools have characteristic features. Many software programs and online services are based on shape similarity, and they have a rich supply of ligand databases. These shape screening tools have rapidly updated in-house databases, can screen large chemical databases rapidly, and therefore can be used for large-scale preliminary reverse screening. Although shape-screening methods have the smallest number of applications, a slow upward trend is evident in recent years (Figure [5A](#F5){ref-type="fig"}). Notably, few studies have applied TarPred, SwissSimilarity, and ChemMapper. The main software and online services based on pharmacophore modeling are PharmMapper and Discovery Studio, each with its own pharmacophore database. PharmMapper is a free online service, whereas Discovery Studio is commercial software, leading to more widespread use of PharmMapper. Among the three reverse screening methods, pharmacophore modeling has the fewest applications before 2016 (Figures [5A,B](#F5){ref-type="fig"}), but its application exhibited a significantly escalating trend in 2017 (Figures [5A,B](#F5){ref-type="fig"}). The reverse docking method has been applied the most; however, the applications of reverse docking have shown a downward trend in recent years. The possible reasons are that some online services, such as TarFisDock, have undergone limited expansion of the existing protein crystal structure grid database, while others, such as idTarget, have a long computational time and high computational cost. Figure [5A](#F5){ref-type="fig"} also illustrates the trend of the practical applications of hybrid methods, with a slow rise in the use of combinations of multiple reverse screening methods for target prediction in recent years.

In addition, we downloaded from PubChem or sketched in Schrödinger the structures of 57 small-molecule ligands whose targets were predicted by reverse screening and further verified experimentally, as reported in these application articles. We used the Cluster Analysis Module in Schrödinger via the two-tiered drop-down menu of Maestro\'s Scripts/Cheminformatics/Clustering of Ligands and a pop-up window titled Clustering based on Volume Overlap to conduct a cluster analysis of these small molecules. Figure [6](#F6){ref-type="fig"} shows representative compounds in the 28 clusters we obtained. Their targets were predicted separately by shape screening, pharmacophore screening and reverse docking. By comparing the structures of these molecules, we may be able to summarize some rules regarding the application ranges of each type of method according to the structures of the query molecules. For example, shape screening may be suitable for a query molecule whose structure shows stereoscopic sense even in a two-dimensional structural view and that is neither very large nor very small (Compounds **3** and **17--23**). Pharmacophore screening is appropriate for query molecules whose structures contain diverse pharmacophore functional groups with a good balance between them (compounds **24--30**). Reverse docking is suitable for the most diverse range of query molecules (compounds **31--39**). We hope that this type of cluster analysis can provide some guidance for the effective use of reverse screening to predict small-molecule targets in the future.

![Twenty-eight representative compounds obtained by the clustering of 57 bioactive compounds for target prediction by different reverse screening methods.](fchem-06-00138-g0006){#F6}

Deficiencies in current reverse screening methods and potential solutions
-------------------------------------------------------------------------

Each reverse screening tool has its own characteristics and appropriate application scope in terms of principle, algorithm and program. However, we need to know the application scopes of these tools in order to select the most appropriate software for making accurate predictions. Thus, a horizontal comparison can provide a better understanding of the advantages and disadvantages of these reverse screening tools and their in-house databases. Some clear deficiencies are present in the programs and in-house databases of current reverse screening tools, making a comparison of the efficiency or the accuracy of target prediction by these tools difficult. None of the online services has a general interface module that can be used to upload and recognize user databases. Because these tools cannot use external databases, evaluating the methods or services based on benchmark databases is infeasible. However, researchers may be able to test the pros and cons of these tools in a way that does not require a benchmark database: we may not need to know the superiority of these tools over each other but may instead need to learn their practical uses and application scopes so that they can be better applied in real-life practice. This comparison requires studies to select some benchmarking query compounds whose known targets represent a large category and whose secondary targets or non-targets have also been studied thoroughly. We can use evaluation indexes such as the enrichment factor and receiver operating characteristic (ROC) curve (Truchon and Bayly, [@B168]) to assess the practical effects of reverse screening tools on the prediction of targets within this large category for other small molecules, thus achieving a horizontal comparison of existing software and online services. This theory is not yet perfected, and successful examples of this approach remain lacking, but it may provide prospects for developing assessments of reverse screening methods and tools.

Moreover, reverse screening servers also lack general-type databases, and their in-house databases are not publicized. We cannot learn the inclusion and exclusion criteria for building these direct databases. Almost all direct databases are bound to the corresponding software, and we are unable to conduct potential data mining. The resources of different online services are also undisclosed, and the services cannot refer to each other\'s databases. Hence, we encourage the developers of all software and online services to disclose their own databases and their construction processes to facilitate user comprehension and utilization. Only in this way can these software databases be better applied in practice, and this approach could also promote the production of more excellent protein-annotated ligand or target structure grid databases for reverse screening.

Previous reviews and prospective studies on reverse screening in molecular target prediction
--------------------------------------------------------------------------------------------

To date, five reviews of reverse screening are available in the literature, which we will discuss briefly below. Readers can also peruse these reviews to deepen their understanding of molecule target prediction algorithms. We will not address other reviews that involve the use of experimental methods or a combination of computational and experimental methods to predict molecular targets (Schenone et al., [@B154]).

Three of the five reviews are similar to our work and provide broad overviews of in silico target fishing. They describe the principles, databases and software involved in computer-aided small-molecule target prediction in terms of different aspects, perspectives and levels (Rognan, [@B146]; Zheng et al., [@B208]; Cereto-Massagué et al., [@B13]). Cereto-Massagué et al. ([@B13]) categorize the methods of target fishing into four classes according to computational principles: molecular similarity methods, protein structure-based methods, data mining/machine learning methods, and methods based on the analysis of bioactivity spectra. Our review covers the principles and applications of the first two classes, molecular similarity and protein structure, but does not address the latter two categories of machine learning and bioactivity spectra. Therefore, readers can review the article by Cereto-Massagué et al. carefully if they are interested in the calculation methods used in those latter two categories. Rognan et al. (Rognan, [@B146]) describe only protein structure-based approaches and further classify them into protein-ligand docking, structure-based pharmacophore searches, binding site similarity measurements, and protein-ligand fingerprints. Based on the principle of receptor structure-based screening, the authors describe these four sub-methods in detail and discuss their pros and cons for target fishing and ligand profiling. That review features descriptions of protein pocket similarity matching and the molecular fingerprinting of protein-ligand interaction information, which is worth reading and comparing to our paper. In addition, Zheng et al. ([@B208]) provide a comprehensive overview of computer-aided drug design methods, including conventional (forward) virtual screening and reverse screening, in terms of five aspects: drug target prediction, drug repositioning, protein-ligand interaction, virtual screening and lead optimization, and ADME/T (absorption, distribution, metabolism, excretion, and toxicity) property prediction. The three reverse screening methods we reviewed are closely related to drug target prediction, drug repositioning and protein-ligand interaction. The above review can help readers systematically study and understand the field of computer-aided virtual screening in drug design.

The other two reviews address only reverse docking and its applications. Specifically, Kharkar et al. ([@B79]) give a detailed description of reverse docking programs and their target databases and further discuss the applications of reverse docking in target identification and the prediction of target functions and off-target effects. Lee et al. ([@B95]) summarize target databases, software programs and services and discuss the application of reverse docking in small-molecule target recognition and drug discovery. They also professionally discuss four issues related to reverse docking that remain to be solved: the standardization of database construction, the inclusion of receptor flexibility, the time-consuming nature of flexible receptor docking, and the inaccuracy of binding free energy calculations and ligand binding pose prediction. Readers may refer to these two reviews for a more comprehensive understanding of reverse docking methods.

Conclusion {#s4}
==========

In this review article, based on previous studies, we selected the three most commonly used types of reverse screening methods, i.e., methods based on shape similarity, pharmacophore modeling and molecular docking, and provided a detailed and comprehensive introduction, including a description of the principles underlying each method and a systematic classification of software, online services, and databases. In addition, we collected nearly all the articles related to the application of computer-aided target reverse screening prediction published since 2000 and analyzed the possible relationships or correlations between compound structures and screening methods by using cluster analysis. The purpose of this review is to help readers quickly understand these three methods and the characteristics of the software and online services based on these methods, to familiarize readers with the status and applications of the different levels of ligand and protein databases used in reverse screening and to provide a better understanding of how existing tools can be applied to molecule target prediction. We strongly believe that more accurate predictions resulting from the familiarity of users with the existing online services and databases will increase the importance of reverse screening in drug repositioning and future research on the pharmacodynamics and pharmacological mechanisms of bioactive compounds.
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4-HT

:   4-Hydroxy-tamoxifen

5-Aza-dC

:   5′-Aza-2′-deoxycytidine

5-HT1AR

:   5-Hydroxytryptamine 1A receptor

5-HT2A

:   5-Hydroxytryptamine receptor 2A

67DiOHC8S

:   6,7-Dihydroxycoumarin-8-sulfate

6BIO

:   6-Bromo-indirubin-3′oxime

ABL

:   BCR-ABL tyrosine kinase

ACE

:   Angiotensin converting enzyme

ACHE

:   Acetylcholinesterase

ACM2

:   Muscarinic acetylcholine receptor 2

ADA

:   Adenosine deaminase

ADH

:   Alcohol dehydrogenase

AdrA3

:   Adenosine receptors A3

ADRB1

:   Human beta-1 adrenergic receptor

AGS-IV

:   Astragaloside IV

AKR1B1

:   Aldo-keto reductase family 1, member B1

ANXA5

:   Annexin A5

Apaf-1

:   Apoptotic protease activating factor-1

APH(2′)-Iva

:   Aminoglycoside-2′-phosphotransferase type Iva

AR

:   Aldose reductase

AR′

:   Androgen receptor

ASA

:   Aspirin

BACE1, ASC

:   Astragalus Salvia compound, Beta-secretase 1

BBR

:   Berberine

Braf

:   B-raf kinase

Bub1

:   Human spindle checkpoint kinase Bub1

CA

:   Carnosic acid

CA1

:   Carbonic anhydrase 1

CA2

:   Carbonic anhydrase 2

CaM

:   Calmodulin

CASP-3

:   Cysteinyl aspartate specific proteinase 3

CB1

:   Cannabinoid receptor 1

CB2

:   Cannabinoid receptor 2

CBS

:   Cystathionine beta-synthase

c-di-GMP

:   Cyclic diguanylate monophosphate

CDK2

:   Cyclin dependent kinase-2

CHS

:   Chitin synthase

CK2

:   Casein kinase 2

CN

:   Calcineurin

CO

:   Curculigo orchioides

Complex I

:   NADH:ubiquinone oxidoreductase

COMT

:   Catechol-O-methyltransferase

COX-1

:   Prostaglandin G/H synthase 1

COX1

:   Cyclooxygenase-1

COX2

:   Cyclooxygenase-2

CT

:   Cryptotanshinone

CYP450

:   Cytochrome p450

D2R

:   Dopamine D2 receptor

DAPDC

:   Diaminopimelate decarboxylase

DAPH

:   Dialkylphosphorylhydrazone

DHFR

:   Dihydrofolate reductase

DHODH

:   Dihydroorotate dehydrogenase

DIP

:   Dipyridamole

DPD

:   Dihydropyrimidine dehydrogenase

DPP-IV

:   Dipeptidyl peptidase IV

DRD2

:   Dopamine receptor D2

EB1

:   Microtubule-associated protein RP/EB family member 1

EGFR

:   Epidermal growth factor receptor

EphA7

:   Ephrin receptor EphA7

ErbB-1

:   ErbB-1 tyrosine kinase

ErbB-2

:   ErbB-2 tyrosine kinase

ERK1

:   Extracellular regulated protein kinases 1

ERR-γ

:   Estrogen-related receptor-γ

ERα

:   Human estrogen receptor alpha

ESR1

:   Estrogen receptor alpha

ESR2

:   Estrogen receptor beta

FAK

:   Focal adhesion kinase

FGFR-4

:   Fibroblast growth factor receptor 4

GAD

:   Ganoderic acid D

GAPDH

:   Glyceraldehyde-3-phosphate Dehydrogenase

GBA3

:   Cytosolic beta-glucosidase

GCN5

:   General control non-derepressible 5

GCR

:   Glucocorticoid receptor

GFW

:   Guizhi Fuling Wan

GK

:   Glucokinase

GMP reductase

:   Guanosine 5′-monophosphate oxidoreductase

GPX1

:   Glutathione peroxidase 1

GR

:   Glucocorticoid receptor

GR′

:   Glutathione reductase

GS, β(1

:   3)-Glucan synthase

GSH-S

:   Glutathione synthetase

GSK3β

:   Glycogen synthase kinase-3 beta

GST

:   Glutathione S-transferase

GSTA1

:   Glutathione S-transferase A1

GSTP1

:   Glutathione s-transferase PI-1

GTPase

:   Guanosine triphosphatase

GTs

:   Ganoderma triterpenes

HDAC2

:   Histone deacetylase 2

HDPR

:   6-hydroxyl-1,6-dihydropurine ribonucleoside

HEXB

:   beta-Hexosaminidase

HGFR

:   Hepatocyte Growth Factor Receptor

HGPRT

:   Hypoxanthine-guanine phosphoribosyltransferase

HIV-1 PR

:   HIV-1 protease

HMGCR

:   3-Hydroxy-3-methylglutaryl-coenzyme A reductase

HpPDF

:   H. pylori PDF

HPRT

:   Hypoxanthine phosphoribosyltransferase

HRAS

:   Harvey rat sarcoma

HRH4

:   Histamine receptor H4

HSD11B1

:   11 beta-Hydroxysteroid dehydrogenase type 1

HSPA8

:   Heat shock protein family A member 8

HSYA

:   Hydroxysafflor yellow A

IDO

:   Indoleamine 2,3-dioxygenase

IDV

:   Indinavir

I-FABP

:   Intestinal fatty acid binding protein

IGF1-R

:   Insulin-like growth factor 1 receptor

IL-2

:   Interleukin-2

IMPDHII

:   Inosine 5′-monophosphate dehydrogenase II

JNK

:   c-Jun N-terminal kinase

LCN-2

:   Lipocalin-2

LDH

:   L-lactate dehydrogenase

LTA4H

:   Leukotriene A4 hydrolase

lysC

:   Lysozyme C

MAO-B

:   Monoamine oxidase B

MAP2K1

:   Mitogen-activated protein kinase kinase 1

MAPK-14

:   Mitogen-activated protein kinase 14

MCDF

:   6-Methyl-1,3,8-trichlorodibenzofuran

MDM2

:   Mouse double minute 2 homolog

MEK1

:   Mitogen-activated protein kinase 1

MIF

:   Migration inhibitory factor

MMP3

:   Metalloproteinase 3

MMP8

:   Metalloproteinase 8

MPO

:   Myeloperoxidase

MTX

:   Methotrexate

NBP

:   DL-3-n-Butylphthalide

NF-kB

:   Nuclear factor kB

NK2 receptor

:   Neurokinin NK2 receptors

NMT

:   N-myristoyltransferase

NQO1

:   NAD(P)H quinone oxidoreductases

Nrf2

:   Nuclear factor erythroid 2-related factor 2

OBA

:   Obacunone

OPRK

:   Kappa opioid receptor

OSC

:   Oxidosqualene cyclase

p38 MAPK

:   p38 Mitogen-activated protein kinase

PARP1

:   Poly \[ADP-ribose\] polymerase 1

PAs

:   Pyrrolizidine alkaloids

PBP4

:   Penicillin binding protein 4

PDE4

:   Phosphodiesterase 4

PDF

:   Peptide deformylase

PDGFR

:   Platelet-Derived Growth Factor Receptor

PDK1

:   Phosphoinositide-dependent kinase-1

PEPCK

:   Phosphoenolpyruvate carboxykinase

PGS

:   Phenolic acid glycoside sulfate

PI-3K

:   Phosphoinositide 3-kinase

PKA

:   cAMP-dependent protein kinase

PLA2

:   Phospholipase A2

PLMF1

:   Periodic leaf movement factor 1

POLB

:   DNA polymerase beta

PPARγ

:   Peroxisome proliferator-activated receptor γ

PPARδ

:   Peroxisome proliferator-activated receptor delta

PRDX3

:   Thioredoxin-dependent peroxide reductase mitochondrial precursor

PRIMA-1

:   P53 reactivation and induction of massive apoptosis

PTP1B

:   Protein tyrosine phosphatase 1B

PTPNT1

:   Protein tyrosine phosphatase non-receptor type 1

RA

:   Rosmarinic acid

RARα

:   Retinoic acid receptor alpha

REN

:   Renin

SAA

:   Salvianolic acid A

SB

:   Salvianolic acid B

SFJD

:   Shufengjiedu Capsule

SHBG

:   Sex hormone-binding globulin

SND

:   Sini decoction

STAT3

:   Signal transducer and activator of transcription 3

SULT1E1

:   Estrogen sulfotransferase

TCDD

:   2,3,7,8-tetrachlorodibenzo-p-dioxin

TDP1

:   Tyrosyl-DNA phosphodiesterase 1

THRa

:   Human thyroid hormone receptor alpha

TOP1

:   DNA topoisomerase 1

UA

:   Ursolic acid

TrxR

:   Thioredoxin reductase

VEGFR-2

:   Vascular endothelial growth factor receptor

VGKC

:   Voltage gated potassium channel

WB

:   Wentilactone B

XO

:   Xanthine oxidase.
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